Race reveals new strategy for cancer drug Bisantrene
Filed with ASX · · 27 pages · English
Earlier from Racura Oncology
- Appendix 4C - quarterly
- Prominent biotech investor leads investment in Race
- First patient treated in Bisantrene trial in Israel
- Bisantrene AML trial to start in Israel
- Bisantrene IND Update
Later from Racura Oncology
- Race Receives $159k R&D Tax Incentive Refund
- December 2019 Quarterly Report
- Race Secures A$1.8m strategic placement
- Race starts preclinical breast cancer study for Bisantrene
- Managing Director Resignation
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology